Pharmacokinetics, Safety and Tolerability of Zongertinib Following Oral Administration in Male and Female Participants of Non-childbearing Potential With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) Compared With Matched Male and Female Participants of Non-childbearing Potential With Normal Hepatic Function (an Open-label, Non-randomised, Single-dose, Parallel, Individual-matched Design Trial)
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs Zongertinib (Primary)
- Indications Liver disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 10 Dec 2024 Planned initiation date changed from 5 Dec 2024 to 16 Dec 2024.
- 26 Nov 2024 New trial record